Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1B | Q01064 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 12/20 | 0.34 |
| ▸ | DRD2 | P14416 | 11/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.34 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.34 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.34 |
| ▸ | TDP2 | O95551 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
| ▸ | PDE1A | P54750 | 1/20 | 0.32 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL390863 | 0.86 | KMT2A (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL390748 | 0.82 | ALDH1A1 (0.44) | MEN1KMT2AALDH1A1 | |
| SCHEMBL390783 | 0.82 | ALDH1A1 (0.41) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1544893 | 0.81 | ALDH1A1 (0.46) | MEN1KMT2AALDH1A1 | |
| SCHEMBL28381052 | 0.81 | MEN1 (0.30) | MEN1KMT2A | |
| SCHEMBL17725440 | 0.78 | MEN1 (0.58) | MEN1KMT2AALDH1A1 | |
| SCHEMBL18454281 | 0.76 | MEN1 (0.35) | MEN1KMT2AHSD11B1ALDH1A1 | |
| SCHEMBL17712727 | 0.75 | MEN1 (0.64) | MEN1KMT2ADRD3DRD2KCNH2 | |
| SCHEMBL19612578 | 0.75 | DRD2 (0.35) | MEN1KMT2ADRD3DRD2KCNH2 | |
| SCHEMBL22211357 | 0.73 | PDE1B (0.35) | PDE1BMEN1KMT2ADRD3DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3212637-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LTD (GB) | 2021-06-02 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2020-05-19 | — | — | US | disclosed |
| CN-107108597-B | Dopamine D3 receptor antagonist compounds | 英立维尔英国有限公司 | 2020-04-17 | — | — | CN | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2019-10-03 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | INDIVIOR UK LIMITED (GB) | 2018-06-19 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | INDIVIOR INC. | 2017-11-23 | — | — | US | disclosed |
| EP-3212637-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | Indivior UK Limited (GB) | 2017-09-06 | — | — | EP | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016067043-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2016-05-06 | — | — | WO | disclosed |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | GLAXO GROUP LIMITED (GB) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10000477-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | PDE1B 854/4885MEN1 4820/4885KMT2A 2745/4885 |
| US-10654842-B2 | Dopamine D3 receptor antagonist compounds | DRD3, DRD2, DRD4 | PDE1B 854/4885MEN1 4820/4885KMT2A 2745/4885 |
| US-20080139532-A1 | Tetrahydrobenzazepine Derivatives as Modulators of Dopamine D3 Receptors (Antipsychotic Agents) | DRD3, DRD2, SLC6A3 | PDE1B 1037/4885MEN1 4671/4885KMT2A 2085/4885 |
| US-20190300514-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | PDE1B 854/4885MEN1 4820/4885KMT2A 2745/4885 |
| US-20170334895-A1 | DOPAMINE D3 RECEPTOR ANTAGONIST COMPOUNDS | DRD3, DRD2, DRD4 | PDE1B 854/4885MEN1 4820/4885KMT2A 2745/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | PDE1B 2649/4885MEN1 3723/4885KMT2A 1947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.